
Silexion starts GMP manufacturing of SIL204 and gets Phase 2/3 trial approval for pancreatic cancer.
Silexion Therapeutics has begun Good Manufacturing Practice (GMP) clinical batch production of SIL204, a next-generation siRNA therapy targeting mutated KRAS in pancreatic cancer. The Helsinki Ethics Committee at Tel Aviv Sourasky Medical Center appr...

